J-P. Metges

428 total citations
21 papers, 320 citations indexed

About

J-P. Metges is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, J-P. Metges has authored 21 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in J-P. Metges's work include Colorectal Cancer Treatments and Studies (10 papers), Gastric Cancer Management and Outcomes (7 papers) and Cancer Treatment and Pharmacology (4 papers). J-P. Metges is often cited by papers focused on Colorectal Cancer Treatments and Studies (10 papers), Gastric Cancer Management and Outcomes (7 papers) and Cancer Treatment and Pharmacology (4 papers). J-P. Metges collaborates with scholars based in France, Spain and Italy. J-P. Metges's co-authors include Michel Robaszkiewicz, Virginie Conan‐Charlet, N Lagarde, C. Bessaguet, A Volant, Laure Gibault, P Lozac’h, Pooja Bhagia, María Maqueda and Wasat Mansoor and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

J-P. Metges

19 papers receiving 314 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J-P. Metges France	6	209	203	163	34	29	21	320
Ken Kato Japan	12	187 0.9×	160 0.8×	133 0.8×	52 1.5×	32 1.1×	42	341
Daisuke Takayanagi Japan	11	245 1.2×	143 0.7×	119 0.7×	37 1.1×	49 1.7×	35	384
И. А. Покатаев Russia	7	141 0.7×	101 0.5×	78 0.5×	35 1.0×	22 0.8×	86	246
Heung-Moon Chang South Korea	9	149 0.7×	170 0.8×	125 0.8×	24 0.7×	82 2.8×	17	286
Heejung Chae South Korea	9	168 0.8×	77 0.4×	78 0.5×	28 0.8×	17 0.6×	45	257
Jim Vasselli United States	8	365 1.7×	121 0.6×	47 0.3×	34 1.0×	22 0.8×	10	406
Brian Quigley United States	9	165 0.8×	58 0.3×	148 0.9×	22 0.6×	17 0.6×	17	241
Svetlana Tafjord Norway	5	282 1.3×	79 0.4×	168 1.0×	26 0.8×	46 1.6×	7	313
Maria Antista Italy	10	205 1.0×	94 0.5×	69 0.4×	61 1.8×	13 0.4×	26	300
Andrea Celotti Italy	9	97 0.5×	226 1.1×	186 1.1×	22 0.6×	65 2.2×	21	311

Countries citing papers authored by J-P. Metges

Since Specialization

Citations

This map shows the geographic impact of J-P. Metges's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J-P. Metges with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J-P. Metges more than expected).

Fields of papers citing papers by J-P. Metges

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J-P. Metges. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J-P. Metges. The network helps show where J-P. Metges may publish in the future.

Co-authorship network of co-authors of J-P. Metges

This figure shows the co-authorship network connecting the top 25 collaborators of J-P. Metges. A scholar is included among the top collaborators of J-P. Metges based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J-P. Metges. J-P. Metges is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Janjigian, Yelena Y., Akihito Kawazoe, Jianming Xu, et al.. (2025). Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial. ESMO Open. 10(10). 105542–105542.

Janjigian, Y. Y., Akihito Kawazoe, Yikui Bai, et al.. (2024). 1400O Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma. Annals of Oncology. 35. S877–S878. 15 indexed citations

Scarpa, Alfonso, Rita T. Lawlor, Anguraj Sadanandam, et al.. (2024). 1150P Search for biomarkers to personalize treatment with streptozotocin plus 5-fluorouracil or everolimus in patients with advanced pancreatic neuroendocrine tumors: The randomized phase III SEQTOR trial (GETNE-1206). Annals of Oncology. 35. S754–S754. 2 indexed citations

Krogh, Merete, Àlex Teulé, Heinz‐Josef Klümpen, et al.. (2024). 1142O Multivariable analysis of streptozotocin plus 5-fluorouracil and everolimus sequences in advanced pancreatic neuroendocrine tumor patients: The SEQTOR trial (GETNE-1206). Annals of Oncology. 35. S750–S750. 1 indexed citations

Wasan, Harpreet, James J. Harding, Jia Fan, et al.. (2023). 101P Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study. Annals of Oncology. 34. S219–S219. 1 indexed citations

Adam, R., Benoist Chibaudel, Stéfano Kim, et al.. (2023). 608P Resectability of colorectal liver metastases (CLM) with aflibercept plus FOLFIRI: Results from a prospective French cohort. Annals of Oncology. 34. S437–S437. 1 indexed citations

Janjigian, Yelena Y., Akihito Kawazoe, Yuxian Bai, et al.. (2023). 1511O Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study. Annals of Oncology. 34. S851–S852. 4 indexed citations

Cousin, Sophie, Carine Bellera, Thibaud Valentin, et al.. (2023). 1920MO Regomune: A phase II study of regorafenib + avelumab in solid tumors - Results of the advanced or metastatic gastrointestinal stromal tumors (mGIST) cohort. Annals of Oncology. 34. S1033–S1033. 2 indexed citations

Tron, Camille, F. Lemaı̂tre, Thierry Lecomte, et al.. (2022). 449TiP Evaluation of regorafenib treatment PERSOnalization based on therapeutic drug monitoring in patients with metastatic colorectal cancer (mCRC): RePERSO study. Annals of Oncology. 33. S739–S740. 1 indexed citations

10.

Cousin, Sophie, Carine Bellera, Rastilav Bahleda, et al.. (2022). 1494P Regomune - a phase II study of regorafenib + avelumab in solid tumors: Results of the soft tissue sarcoma (STS) cohort. Annals of Oncology. 33. S1230–S1230. 3 indexed citations

11.

Salazar, Ramón, Merete Krogh, Àlex Teulé, et al.. (2022). LBA45 Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206). Annals of Oncology. 33. S1412–S1412. 21 indexed citations

12.

Kato, Ken, Manan Shah, Peter C. Enzinger, et al.. (2020). LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study. Annals of Oncology. 31. S1192–S1193. 98 indexed citations

13.

Hammel, Pascal, Laurent Mineur, J-P. Metges, et al.. (2017). A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180). Annals of Oncology. 28. v211–v211. 8 indexed citations

14.

Metges, J-P., Jaafar Bennouna, Michel Rivoire, et al.. (2016). PD-032 Is there an impact of the number of metastases in the outcome of potentially resectable metastatic colorectal cancer patients receiving bevacizumab-based regimen in 1st line? Results of the PICASSO study. Annals of Oncology. 27. ii114–ii114.

15.

Metges, J-P., Jean‐François Ramée, Olivier Dupuis, et al.. (2012). Panerb Study: Which Category of Patients, Suffering from Metastatic Colorectal Cancer, Can Benefit From Panitumumab Treatment After Cetuximab-Based Regimen Failure?. Annals of Oncology. 23. ix196–ix196. 2 indexed citations

16.

Metges, J-P., Jean‐François Ramée, Jean‐Luc Raoul, et al.. (2011). What is the benefit for patients suffering from metastatic colorectal cancer (mCRC) after bevacizumab-based regimen (BBR), cetuximab-based regimen (CBR), and panitumumab (P)?. Journal of Clinical Oncology. 29(4_suppl). 595–595. 3 indexed citations

17.

Metges, J-P., E. Gamelin, Roger Faroux, et al.. (2009). 3603 Management of unresectable metastatic colorectal cancer (MRCC) in the real world with successive regimens with targeted therapies (Bevacizumab and cetuximab): the experience of the OMIT Bretagne Pays de Loire. European Journal of Cancer Supplements. 7(2). 209–209. 1 indexed citations

18.

Metges, J-P., Laure Gibault, Virginie Conan‐Charlet, et al.. (2006). Reply: Her2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus?. British Journal of Cancer. 94(8). 1214–1215. 1 indexed citations

19.

Gibault, Laure, J-P. Metges, Virginie Conan‐Charlet, et al.. (2005). Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. British Journal of Cancer. 93(1). 107–115. 122 indexed citations

20.

Metges, J-P., et al.. (2001). Métastases gastroduodénales : un mode de révélation exceptionnel du cancer du poumon.Étude de deux cas et revue de la littérature. La Revue de Médecine Interne. 22(5). 465–468. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact